Margie Tabuga Borra-Garske, Palo Alto, CA (US); Oscar Alvizo, Fremont, CA (US); Lillian Jasmine Miller, Saratoga, CA (US); Jesse B. Slaton, Sacramento, CA (US); Aksiniya Lyubenova Petkova, Sunnyvale, CA (US); Nandhitha Subramanian, Cambridge (GB); Joshua Kolev, Califon, NJ (US); Anna Fryszkowska, New York, NY (US); Agustina Rodriguez-Granillo, West Newton, MA (US); and Grant Murphy, Princeton, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Dec. 14, 2020, as Appl. No. 17/120,646.
Application 17/120,646 is a division of application No. 16/460,147, filed on Jul. 2, 2019, granted, now 10,889,806.
Claims priority of provisional application 62/695,587, filed on Jul. 9, 2018.
Claims priority of provisional application 62/822,301, filed on Mar. 22, 2019.
Prior Publication US 2021/0102179 A1, Apr. 8, 2021
1. An engineered pantothenate kinase polypeptide comprising an amino acid sequence having at least 85% sequence to SEQ ID NO: 2, wherein said engineered pantothenate kinase polypeptide comprises an amino acid substitution set corresponding to amino acid positions F15L, V27N, and W283H/L in SEQ ID NO: 2, wherein said engineered pantothenate kinase polypeptide has increased ability to convert ethynyl glyceraldehyde to ethynyl glyceraldehyde phosphate when compared to the wild-type polypeptide having the amino acid sequence of SEQ ID NO: 2.